X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21) 21
female (18) 18
aged (15) 15
middle aged (15) 15
endocrinology & metabolism (13) 13
osteoporosis (13) 13
index medicus (11) 11
aged, 80 and over (9) 9
denosumab (9) 9
double-blind method (9) 9
bone density - drug effects (8) 8
osteoporosis, postmenopausal - drug therapy (8) 8
postmenopausal women (8) 8
adult (7) 7
alendronate (7) 7
bone-mineral density (7) 7
male (7) 7
raloxifene (7) 7
animals (6) 6
mice (6) 6
obstetrics & gynecology (5) 5
postmenopause (5) 5
treatment outcome (5) 5
women (5) 5
abridged index medicus (4) 4
antibodies, monoclonal, humanized (4) 4
antibodies, monoclonal, humanized - therapeutic use (4) 4
bone density (4) 4
bone density conservation agents - adverse effects (4) 4
bone density conservation agents - therapeutic use (4) 4
estrogen (4) 4
fractures, bone - prevention & control (4) 4
medicine, general & internal (4) 4
nonvertebral fractures (4) 4
postmenopause - drug effects (4) 4
raloxifene hydrochloride - administration & dosage (4) 4
vertebral fracture risk (4) 4
administration, oral (3) 3
antibodies, monoclonal - adverse effects (3) 3
antibodies, monoclonal, humanized - adverse effects (3) 3
bone density conservation agents - pharmacology (3) 3
bone remodeling - drug effects (3) 3
cell biology (3) 3
chronic pain (3) 3
clinical trial (3) 3
drug administration schedule (3) 3
femur neck - drug effects (3) 3
fractures (3) 3
opioid (3) 3
osteoblasts - metabolism (3) 3
osteoclast differentiation (3) 3
osteoporosis, postmenopausal - complications (3) 3
osteoprotegerin ligand (3) 3
phosphorylation (3) 3
placebos (3) 3
postmenopause - physiology (3) 3
raloxifene hydrochloride - therapeutic use (3) 3
rank ligand - adverse effects (3) 3
rankl (3) 3
research (3) 3
risedronate (3) 3
risk (3) 3
risk factors (3) 3
selective estrogen receptor modulators - pharmacology (3) 3
severity of illness index (3) 3
therapy (3) 3
vertebral fractures (3) 3
3t3 cells (2) 2
abuse potential (2) 2
addiction (2) 2
administration, intravaginal (2) 2
alendronate - administration & dosage (2) 2
alendronate - adverse effects (2) 2
alendronate - therapeutic use (2) 2
aluminum (2) 2
amino acid sequence (2) 2
analysis of variance (2) 2
anesthesiology (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - pharmacology (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
antibodies, monoclonal, humanized - pharmacology (2) 2
atrophy - drug therapy (2) 2
atrophy - pathology (2) 2
biochemistry & molecular biology (2) 2
biomarkers (2) 2
biomarkers - blood (2) 2
bmd (2) 2
bone density conservation agents - administration & dosage (2) 2
breast-cancer (2) 2
breast-cancer patients (2) 2
calcitonin (2) 2
care and treatment (2) 2
cell line (2) 2
cells (2) 2
cells, cultured (2) 2
cocaine (2) 2
cyclic amp - biosynthesis (2) 2
diphosphonates - therapeutic use (2) 2
dopamine (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2009, Volume 361, Issue 8, pp. 756 - 765
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 01/2010, Volume 25, Issue 1, pp. 72 - 81
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 2012, Volume 27, Issue 1, pp. 211 - 218
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 02/2014, Volume 29, Issue 2, pp. 450 - 457
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 12/2007, Volume 22, Issue 12, pp. 1832 - 1841
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 09/2012, Volume 97, Issue 9, pp. 3161 - 3169
Journal Article
Pain, ISSN 0304-3959, 06/2019, Volume 160, Issue 6, pp. 1374 - 1382
NKTR-181, a new molecular entity, mu-opioid receptor agonist with an inherently slow rate of central nervous system (CNS) entry, was designed to provide... 
UNITED-STATES | MISUSE | SUMMIT-07 | NKTR-181 | Opioid | COCAINE | PREVALENCE | NEUROSCIENCES | Chronic pain | ADDICTION | CLINICAL NEUROLOGY | DRUG-ABUSE | Chronic low-back pain | THERAPY | FORMULATIONS | DISABILITY | DOPAMINE | ANESTHESIOLOGY | Research Paper
Journal Article
Pain Medicine, ISSN 1526-2375, 09/2019
Abstract Objective To evaluate the human abuse potential, pharmacokinetics, pharmacodynamics, and safety of oral NKTR-181 (oxycodegol), a novel full mu-opioid... 
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 04/2015, Volume 100, Issue 4, pp. 1335 - 1342
Journal Article
Pain medicine (Malden, Mass.), ISSN 1526-2375, 07/2019
To evaluate the long-term safety of NKTR-181, a novel mu-opioid receptor agonist that may have reduced human abuse potential, in patients with moderate to... 
Journal Article